News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,099 Results
Type
Article (42442)
Company Profile (436)
Press Release (673221)
Multimedia
Podcasts (79)
Webinars (13)
Section
Business (209137)
Career Advice (2157)
Deals (36031)
Drug Delivery (104)
Drug Development (83603)
Employer Resources (173)
FDA (16463)
Job Trends (15124)
News (353453)
Policy (33152)
Tag
Academia (2650)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50999)
ALS (95)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (139)
Approvals (16454)
Artificial intelligence (269)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11859)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (82)
Brain cancer (27)
Breast cancer (287)
Cancer (2316)
Cardiovascular disease (185)
Career advice (1814)
Career pathing (30)
CAR-T (157)
Cell therapy (444)
Cervical cancer (19)
Clinical research (67795)
Collaboration (878)
Compensation (532)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (253)
Cystic fibrosis (105)
Data (2232)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (275)
Diagnostics (6441)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (88113)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (116339)
Executive appointments (743)
FDA (17732)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (784)
Gene editing (113)
Generative AI (20)
Gene therapy (328)
GLP-1 (747)
Government (4510)
Grass and pollen (4)
Guidances (59)
Healthcare (19187)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (131)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (349)
IPO (16804)
IRA (43)
Job creations (3709)
Job search strategy (1514)
Kidney cancer (10)
Labor market (38)
Layoffs (497)
Leadership (18)
Legal (8013)
Liver cancer (76)
Lung cancer (328)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (313)
MASH (69)
Medical device (13556)
Medtech (13561)
Mergers & acquisitions (19767)
Metabolic disorders (718)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2004)
NextGen: Class of 2025 (6777)
Non-profit (4576)
Now hiring (39)
Obesity (385)
Opinion (223)
Ovarian cancer (77)
Pain (90)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (111)
Peanut (47)
People (58731)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21307)
Phase II (29913)
Phase III (22117)
Pipeline (1209)
Policy (146)
Postmarket research (2601)
Preclinical (9142)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6019)
Recruiting (66)
Regulatory (22774)
Reports (46)
Research institute (2421)
Resumes & cover letters (374)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (140)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3765)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (39)
The Weekly (49)
Vaccines (705)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Today (166)
Last 7 days (869)
Last 30 days (2680)
Last 365 days (33844)
2025 (10893)
2024 (36338)
2023 (41057)
2022 (52323)
2021 (56822)
2020 (55017)
2019 (47551)
2018 (35834)
2017 (33114)
2016 (32447)
2015 (38471)
2014 (32255)
2013 (27165)
2012 (29283)
2011 (29936)
2010 (28053)
Location
Africa (739)
Alabama (58)
Alaska (7)
Arizona (242)
Arkansas (14)
Asia (39326)
Australia (6543)
California (6240)
Canada (2022)
China (533)
Colorado (272)
Connecticut (286)
Delaware (149)
Europe (86150)
Florida (910)
Georgia (206)
Idaho (57)
Illinois (552)
India (25)
Indiana (310)
Iowa (12)
Japan (163)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (908)
Massachusetts (4742)
Michigan (226)
Minnesota (397)
Mississippi (2)
Missouri (86)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1759)
New Mexico (30)
New York (1762)
North Carolina (1033)
North Dakota (8)
Northern California (2701)
Ohio (206)
Oklahoma (14)
Oregon (38)
Pennsylvania (1389)
Puerto Rico (12)
Rhode Island (34)
South America (1118)
South Carolina (22)
South Dakota (1)
Southern California (2328)
Tennessee (101)
Texas (923)
United States (23650)
Utah (183)
Virginia (149)
Washington D.C. (63)
Washington State (573)
West Virginia (3)
Wisconsin (54)
716,099 Results for "click therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Press Releases
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
April 15, 2025
·
10 min read
Business
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.
April 1, 2024
·
12 min read
Business
Click Therapeutics and Boehringer Ingelheim Announce FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that the investigational CT-155 prescription digital therapeutic (PDT), co-developed by Boehringer Ingelheim and Click Therapeutics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
January 4, 2024
·
6 min read
Pharm Country
Click Therapeutics Announces Participation in November Investor Conferences
Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced that Randall Stanicky, Chief Financial Officer, will participate in the following investor conferences this month.
November 7, 2023
·
1 min read
Pharm Country
Click Therapeutics Announces Participation in Upcoming Technology and Biotechnology Investor Events
Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced that company management will participate in the following investor events this month.
August 3, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
·
8 min read
Pharm Country
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
Click Therapeutics, Inc. today announced the launch of its second active randomized clinical trial in migraine, ReMMiD-C, Reduction in Monthly Migraine Days-CGRP study, a fully remote and decentralized trial designed to investigate the efficacy and safety of digital therapeutics in reducing the number of monthly migraine days for adults diagnosed with episodic migraine currently receiving Calcitonin-Gene-Related Peptide (CGRP) inhibitor therapy.
August 2, 2023
·
7 min read
1 of 71,610
Next
